J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer today and set a price target of $30.00. The company’s shares closed yesterday at $24.66. Take advantage of TipRanks Premium at 50% ...

Currently, the analyst consensus on Pfizer is a Hold with an average price target of $28.60, representing a 15.98% upside. In a report released today, J.P. Morgan also maintained a Hold rating on the ...

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

(Reuters) -Pfizer Inc said on Monday it has filed a second lawsuit against Metsera and its controlling shareholders, as well as Novo Nordisk in a Delaware federal court, accusing them of ...

Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s ...

The stock has surged roughly 157% YTD, yet both Wall Street and Seeking Alpha’s Quant Rating keep a Hold due to valuation concerns. Piper Sandler lifted its price target to $210 from ... 100% of those ...

Discover top large-cap value stocks using YCharts & Ben Graham Formula. Find high-yield dividend picks for October 2024.

Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s ...